Comparison

Lixisenatide vs. Semaglutid

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Lixisenatide	Semaglutid
Switzerland	—	Prescription
Germany	Prescription	Prescription
JP	Prescription	—
United States	Unapproved	Prescription

Full entries

Frequently asked questions

What is the difference between Lixisenatide and Semaglutid?: Lixisenatide is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Lixisenatide or Semaglutid?: The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Lixisenatide and Semaglutid in Germany and the United States?: Germany: Lixisenatide — Prescription, Semaglutid — Prescription. United States: Lixisenatide — Unapproved, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Lixisenatide

Semaglutid

Switzerland

—

Prescription

Germany

Prescription

—

United States

Unapproved

Prescription

Frequently asked questions

What is the difference between Lixisenatide and Semaglutid?

Lixisenatide is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Lixisenatide or Semaglutid?

The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Lixisenatide and Semaglutid in Germany and the United States?

Germany: Lixisenatide — Prescription, Semaglutid — Prescription. United States: Lixisenatide — Unapproved, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.